AlphAIAlphAI — Financial news for AI agents
SEC EDGARSEP 151 min read$UTHR

ROTHBLATT MARTINE A sold $4.8M of UTHR (indirect holdings)

ROTHBLATT MARTINE A (Chairperson & CEO) sold 9,500 indirectly-held shares of UNITED THERAPEUTICS Corp (UTHR) at an average of $504.12 ($502.15–$506.48, $4.79M total) across 5 trades on 2026-09-14 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · ROTHBLATT MARTINE A
Published Sep 15, 2026, 8:34 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 15, 2026, 8:54 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$UTHR
Bearish
medium confidence
Mentioned
$UTHR
Relevance
5/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$UTHRBearishLow
01

Why it matters

The sale represents a $4.8M reduction in the CEO's stake, which could be interpreted as a negative signal by investors.

02

Market read

Primary insider sale; modest materiality; limited trading relevance.

03

What to watch

Potential upcoming corporate actions or financing needs not disclosed in the filing.

Relevance 5/10Novelty 6/10Timing: post‑market 2026‑09‑14

Background

SEC Form 4 filing discloses insider transactions; required to be reported within two business days.

Company-level read

Ticker impact

$UTHRBearishMedium confidence
Context

CEO Martine Rothblatt sold $4.8M of UTHR shares via a 10b5‑1 plan on 2026‑09‑14.

Expected impact

Possible modest downside pressure over the next few days.

Evidence & confidence

Large insider sell at market price, executed through a pre‑arranged plan, suggests personal liquidity need rather than company fundamentals.

Market effects

Sector

Minimal impact on the biotech/therapeutics sector; isolated to United Therapeutics.

Regional

US market only; no broader regional effect.

Global

Low; the filing is company‑specific.

Counterpoint

What could challenge this read

The sale may be purely liquidity‑driven under a 10b5‑1 plan and not reflect underlying business concerns.

Key entities

  • company
    United Therapeutics Corp

    Biopharmaceutical company listed on NYSE under ticker UTHR.

  • insider
    Martine A. Rothblatt

    Chairperson & CEO of United Therapeutics.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

UTHR insider trading history →

Related articles

OCT 8
$UTHRMed

UTHR Maintained by RBC Capital -- Price Target Raised to $708

RBC Capital maintained an 'Outperform' rating for United Therapeutics (UTHR) and raised its price target from $677 to $708, citing confidence in the company's performance. GuruFocus estimates UTHR is 24% overvalued with a GF Value of $429.35, while the stock trades at $532.19. The company has a GF Score of 84/100, strong financial health, and a P/E ratio of 19.04x.

gurufocus.com1 min